151 related articles for article (PubMed ID: 20364021)
1. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Chiba Y; Hashimoto N; Tsuboi A; Oka Y; Murao A; Kinoshita M; Kagawa N; Oji Y; Hosen N; Nishida S; Sugiyama H; Yoshimine T
Jpn J Clin Oncol; 2010 May; 40(5):395-403. PubMed ID: 20364021
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
4. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Chiocca EA; Aguilar LK; Bell SD; Kaur B; Hardcastle J; Cavaliere R; McGregor J; Lo S; Ray-Chaudhuri A; Chakravarti A; Grecula J; Newton H; Harris KS; Grossman RG; Trask TW; Baskin DS; Monterroso C; Manzanera AG; Aguilar-Cordova E; New PZ
J Clin Oncol; 2011 Sep; 29(27):3611-9. PubMed ID: 21844505
[TBL] [Abstract][Full Text] [Related]
5. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Hashimoto N; Tsuboi A; Kagawa N; Chiba Y; Izumoto S; Kinoshita M; Kijima N; Oka Y; Morimoto S; Nakajima H; Morita S; Sakamoto J; Nishida S; Hosen N; Oji Y; Arita N; Yoshimine T; Sugiyama H
Cancer Immunol Immunother; 2015 Jun; 64(6):707-16. PubMed ID: 25772149
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
7. Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Ishikawa E; Yamamoto T; Sakamoto N; Nakai K; Akutsu H; Tsuboi K; Takano S; Matsumura A
Neurol Med Chir (Tokyo); 2010; 50(8):638-44. PubMed ID: 20805645
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.
Liu G; Akasaki Y; Khong HT; Wheeler CJ; Das A; Black KL; Yu JS
Oncogene; 2005 Aug; 24(33):5226-34. PubMed ID: 15897911
[TBL] [Abstract][Full Text] [Related]
9. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
[TBL] [Abstract][Full Text] [Related]
10. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Heimberger AB; Sun W; Hussain SF; Dey M; Crutcher L; Aldape K; Gilbert M; Hassenbusch SJ; Sawaya R; Schmittling B; Archer GE; Mitchell DA; Bigner DD; Sampson JH
Neuro Oncol; 2008 Feb; 10(1):98-103. PubMed ID: 18079360
[TBL] [Abstract][Full Text] [Related]
11. Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy.
Yamini B; Yu X; Pytel P; Galanopoulos N; Rawlani V; Veerapong J; Bickenbach K; Weichselbaum RR
Clin Cancer Res; 2007 Oct; 13(20):6217-23. PubMed ID: 17947489
[TBL] [Abstract][Full Text] [Related]
12. Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated αβ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma.
Kanemura Y; Sumida M; Okita Y; Yoshioka E; Yamamoto A; Kanematsu D; Handa Y; Fukusumi H; Inazawa Y; Takada AI; Nonaka M; Nakajima S; Mori K; Goto S; Kamigaki T; Shofuda T; Moriuchi S; Yamasaki M
Anticancer Res; 2017 Jul; 37(7):3921-3932. PubMed ID: 28668896
[TBL] [Abstract][Full Text] [Related]
13. [Multidisciplinary therapy using interferon and immunological evaluation for glioma patients: two-color analysis of T cell subsets].
Numa Y; Kawamoto K; Matsumura H
No Shinkei Geka; 1991 Feb; 19(2):121-8. PubMed ID: 1708857
[TBL] [Abstract][Full Text] [Related]
14. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
[TBL] [Abstract][Full Text] [Related]
15. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
17. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
Chua D; Krzakowski M; Chouaid C; Pallotta MG; Martinez JI; Gottfried M; Curran W; Throuvalas N
Clin Lung Cancer; 2010 May; 11(3):176-81. PubMed ID: 20439193
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
19. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Gerber DE; Grossman SA; Zeltzman M; Parisi MA; Kleinberg L
Neuro Oncol; 2007 Jan; 9(1):47-52. PubMed ID: 17108062
[TBL] [Abstract][Full Text] [Related]
20. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
